Latest News and Press Releases

Preconditioning with lymphodepletion linked to stronger MAR-T cells response and suggests enhanced anti-tumor activity Highest enrollment since study launch underscores momentum and signals a...

HOUSTON, May 19, 2025 (GLOBE NEWSWIRE) -- MARKER THERAPEUTICS, INC. (Nasdaq: MRKR), a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapies for...

Preliminary data from study in patients with lymphoma enrolled at City of Hope National Medical Center was presented at the 11th Global Summit on Hematologic Malignancies in Whistler, BC, Canada ...

Lead program in patients with lymphoma demonstrated preliminary safety and efficacy results with sustained complete response in first study participant treated with MT-601 (Neldaleucel) following CAR...

HOUSTON, Jan. 22, 2024 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapies for...

HOUSTON, May 31, 2023 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapies for...

2022 CLINICAL AND REGULATORY HIGHLIGHTS Awarded $2 million grant from U.S. Food and Drug Administration (FDA) for the Phase 2 ARTEMIS trial of MT-401 in post-transplant acute myeloid leukemia...

NASHVILLE, Tenn., March 16, 2021 (GLOBE NEWSWIRE) -- Aegis Sciences Corporation, a leading healthcare company that provides clinically innovative COVID-19 and medication compliance testing services,...

MEMPHIS, Tenn., March 29, 2017 (GLOBE NEWSWIRE) -- A historical marker commemorating the final flight of Dr. Martin Luther King Jr. will be dedicated at Memphis International Airport on April 3....

STONY BROOK, NY--(Marketwire - January 7, 2010) - Applied DNA Sciences (OTCBB: APDN) announced that it has signed an exclusive Supply Agreement with a renowned luxury brand with global distribution,...